Could a weekly shot help more people donate part of their liver?
NCT ID NCT07718126
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether a 12-week program combining a weekly injection of mazdutide (a drug that targets gut hormones) with lifestyle counseling can quickly reduce liver fat in overweight or obese people who want to donate part of their liver but are temporarily disqualified due to fatty liver disease. Participants are randomly assigned to receive either mazdutide or a placebo, plus standard lifestyle advice. The main goal is to see if more people in the mazdutide group achieve complete resolution of liver fat without worsening liver damage, potentially allowing them to safely proceed with donation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a novel GLP-1/GCG receptor dual agonist called mazdutide, given as a weekly injection
- What this could lead to
- If successful, this approach could help more people with fatty liver disease become eligible to donate a portion of their liver, expanding the donor pool and improving outcomes for transplant recipients.
- What could go wrong
- This is an early-to-mid-stage trial with only 60 participants, so results may not apply broadly. The drug can cause gastrointestinal side effects, and not all participants may achieve the desired liver fat reduction.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC STEATOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital (The First Affiliated Hospital of USTC)
Hefei, Anhui, 230036, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug aims to reverse liver scarring in MASH cirrhosis
- Experimental drug aims to stop liver failure in MASH cirrhosis
- Could a probiotic supplement help reverse fatty liver?
- Could a probiotic supplement help reverse fatty liver?
- Could a fatty liver fuel Alzheimer's? new scan aims to find out
- New MRI methods could spot liver damage earlier